long-lasting injectable naltrexone — Competitive Intelligence Brief

long-lasting injectable naltrexone (long-lasting injectable naltrexone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor antagonist. Area: Psychiatry / Addiction Medicine.

marketed Opioid receptor antagonist Opioid receptors (mu, delta, kappa) Psychiatry / Addiction Medicine Small molecule

Target snapshot

long-lasting injectable naltrexone (long-lasting injectable naltrexone) — State University of New York - Upstate Medical University. Naltrexone is an opioid receptor antagonist that blocks the effects of opioids and reduces cravings for opioid use.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
long-lasting injectable naltrexone TARGET	long-lasting injectable naltrexone	State University of New York - Upstate Medical University	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
Nalmefene HCl injection	Nalmefene HCl injection	Leiden University Medical Center	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
Oral Naltrexone	Oral Naltrexone	New York State Psychiatric Institute	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
XR-NTX 380 mg, intramuscular injection	XR-NTX 380 mg, intramuscular injection	University of Pennsylvania	marketed	Opioid receptor antagonist	Mu opioid receptor (primary); delta and kappa opioid receptors
Methylnaltrexone (MNTX)	Methylnaltrexone (MNTX)	Bausch Health Americas, Inc.	marketed	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)
Naltrexone Pill	Naltrexone Pill	Albert Einstein Healthcare Network	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
MOVANTIK™ (naloxegol)	MOVANTIK™ (naloxegol)	Massachusetts General Hospital	marketed	Peripheral opioid receptor antagonist	Mu-opioid receptor (peripheral)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor antagonist class)

1. Albert Einstein Healthcare Network · 1 drug in this class
2. Cephalon · 1 drug in this class
3. Leiden University Medical Center · 1 drug in this class
4. New York State Psychiatric Institute · 1 drug in this class
5. Paion UK Ltd. · 1 drug in this class
6. Pocket Naloxone Corp · 1 drug in this class
7. State University of New York - Upstate Medical University · 1 drug in this class
8. Texas Tech University · 1 drug in this class
9. The Scripps Research Institute · 1 drug in this class
10. University of North Carolina, Chapel Hill · 1 drug in this class